Nine Diagnostics was selected to present at the 2025 MIT Health Science Forum, hosted by the MIT Industrial Liaison Program (ILP) and MIT Startup Exchange. Held on May 8, 2025, the forum convened MIT researchers, global industry leaders, and select startups to showcase cutting-edge developments at the intersection of science, technology, and health.
The event focused on five key areas shaping the future of healthcare:
AI for biomolecular modeling
Biomanufacturing for cell and gene therapies
Drug delivery
Precision oncology
Advanced diagnostics
Nine Diagnostics presented its AI-powered nanosensor platform, which enables real-time insights into disease biology using small-volume patient samples. The technology supports both early detection and treatment monitoring by integrating multidimensional data—including molecular signals, patient demographics, and clinical context—into a unified decision support framework.
The forum provided an opportunity for thought leaders and startups to engage in cross-sector dialogue, explore translational partnerships, and accelerate innovation across biomedical domains. Being selected to present reflects Nine Diagnostics’ leadership in advancing precision diagnostics and its alignment with MIT’s mission to drive impactful healthcare innovation.
Learn more about the event here: MIT ILP Health Science Forum 2025
Nine Diagnostics, a leader in AI-enabled nanosensor technology, has been selected to participate in the American Cancer Society’s BrightEdge Entrepreneurs Program, a highly selective initiative designed to accelerate the most promising oncology-focused startups. This selection marks another significant milestone for Nine Diagnostics as it continues to drive innovation in cancer treatment selection, dosing, optimization, and monitoring.
Nine Diagnostics Joins American Cancer Society’s BrightEdge Entrepreneurs Program
“What we’d like to do is triage all gynaecological disease – so when someone comes in with a complaint, can we give doctors a tool that quickly tells them it’s more likely to be a cancer or not, or this cancer than that.” -Daniel Heller
Building Novel Solutions for Women's Health
Leading Dutch and U.S. companies are joining forces to develop groundbreaking diagnostic tools and treatments in gynecological health.
The collaboration is supported by the Netherlands Innovation Network in Boston - Dutch Ministry of Economic Affairs.
Nine Diagnostics is proud to announce its acceptance into the latest cohort of the Merck Digital Sciences Studio (MDS Studio), a digital accelerator designed to enable the next generation of technologies for drug discovery and development, including artificial intelligence and machine learning. MDS Studio was founded to offer support for early-stage biomedical startups providing strategic guidance, direct investment, and connection opportunities within Merck.
Nine Diagnostics Selected for Merck Digital Sciences Studio Cohort 3
Nine Diagnostics, a leader in cutting-edge medical diagnostics, is honored to announce that it has been awarded the Novo Nordisk Golden Ticket for a residency at LabCentral, hosted by the Novo Nordisk Bio Innovation Hub. This incredible opportunity is a significant milestone for the company, reinforcing its commitment to improving healthcare through advanced technologies that enable faster, more personalized diagnostics.
Nine Diagnostics Wins Novo Nordisk Golden Ticket for LabCentral Residency
Functional Precision Medicine by Design
Determining treatment effectiveness, discovering new biology powered by our AI-enabled nanosensor technology.
